[16]
With respect to the object of the legislative scheme, this court has stated, on several occasions, that the basic purpose of the
Patented Medicines (Notice of Compliance) Regulations
is to prevent patent infringement. (See, for example,
Apotex Inc. v. Canada (Minister of National Health and Welfare) et al.
(1997), 219 N.R. 151; 76 C.P.R.(3d) 1 (F.C.A.) at p. 11;
ICN Pharmaceuticals Inc. et al. v. Patented Medicines Prices Review Board et al.
(1996), 200 N.R. 376; 68 C.P.R.(3d) 417 (F.C.A.) at p. 424;
Merck Frosst Canada Inc. v. Canada (Minister of National Health and Welfare)
(1994), 169 N.R. 342; 55 C.P.R.(3d) 302 (F.C.A.) at p. 314 (F.C.A.);
Bayer AG and Miles Canada Inc. v. Canada (Minister of National Health and Welfare) and Apotex Inc.
(1993), 163 N.R. 183; 51 C.P.R.(3d) 329 (F.C.A.) at pp. 331-332 (C.P.R.)).